Companies · Biotechnology
SOLON · Biotechnology
Diligence memoA one-page analyst read on Locus Solutions, LLC/OH — recommendation, valuation, rhythm, risks.→Locus Solutions, LLC/OH looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Locus Solutions, LLC/OH behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Locus Solutions, LLC/OH is one of 4293 Biotechnology companies tracked from SOLON. By capital raised it ranks in the upper tier (ahead of 72% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 72% of sector peers (real $). Modeled value above 55% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #137 of 197.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Mt McKinley Medical Holding Corp USA | Series B | $40.0M | $738.4M | 4.41× |
| YAP Therapeutics Inc | Series B | $30.1M | $618.3M | 3.69× |
| Pinteon Therapeutics, Inc. | Series B | $39.2M | $603.8M | 3.60× |
| OncXerna Therapeutics, Ltd. | Series B | $30.0M | $591.4M | 3.53× |
| EpiBiologics, Inc. | Series B | $30.0M | $570.2M | 3.40× |
| GIOGI Ltd | Series B | $27.3M | $554.5M | 3.31× |
| SonoThera, Inc. | Series B | $30.4M | $550.9M | 3.29× |
| Perceive Biotherapeutics, Inc. | Series B | $40.0M | $544.6M | 3.25× |
| GIOCAN Ltd | Series B | $24.5M | $498.6M | 2.97× |
| GIODIA Ltd | Series B | $24.5M | $498.6M | 2.97× |
| GIOHEALTH Ltd | Series B | $24.5M | $498.6M | 2.97× |
| Cerapedics Inc | Series B | $99.1M | $492.3M | 2.94× |
| Locus Solutions, LLC/OH this company | Series B | $25.0M | $84.9M | 0.51× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series B | $20.3M | 2019-11-21 | $112.7M | $805.2M | 90% |
| Series B | $4.7M | 2022-05-09 | $26.3M | $84.9M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Donald M. Sweeney | — | 1 other | 2019-11 |
| Alvaro M. Pascotto | — | — | 2019-11 |
| Alvaro M Pascottto | — | — | 2022-05 |
| Andrew M Lefkowitz | — | — | 2019-11 |
| David M Heidecorn | — | — | 2019-11 |
| Donald M Sweeny | — | — | 2022-05 |
| John M Rea | — | — | 2019-11 |
| Karthik M Karathur | — | — | 2022-05 |
| Karthik N. Karathur | — | — | 2019-11 |
| Sean M Farmer | — | — | 2019-11 |
| Tom M Vetrano | — | — | 2019-11 |
Locus Solutions, LLC/OH is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Lonestar Medicines, Inc. | Biotechnology | Series B | $25.0M | $92.4M | same sector · same stage |
| Angiex, Inc. | Biotechnology | Series B | $24.9M | $98.6M | same sector · same stage |
| Insite Vision Inc | Biotechnology | Series B | $24.6M | $94.5M | same sector · same stage |
| Brainbox Solutions, Inc. | Biotechnology | Series B | $26.0M | $67.8M | same sector · same stage |
| Polarityte, Inc. | Biotechnology | Series B | $24.0M | $69.4M | same sector · same stage |
| Promaxo Holdings, Inc. | Biotechnology | Series B | $26.8M | $92.0M | same sector · same stage |
| Pacegenix, Inc. | Biotechnology | Series B | $22.5M | $77.8M | same sector · same stage |
| Ramona Optics, Inc. | Biotechnology | Series B | $27.9M | $91.4M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Locus Biosciences, Inc. | Biotechnology | Series B | $213.3M | 91% |
| Gene Solutions Llc | Biotechnology | Series A | $192.7M | 86% |
| Ufovax, LLC | Biotechnology | Series A | $363.3M | 83% |
| MyGenetics LLC | Biotechnology | Pre-Seed | $10.5M | 83% |
| Bugworks Research, Inc. | Biotechnology | Series B | $56.4M | 83% |
| Mosaic Biosciences, Inc. | Biotechnology | Series A | $176.4M | 82% |
| Chemical Solutions Group, LLC | Biotechnology | Series A | $361.5M | 82% |
| Portal Biotechnologies, Inc. | Biotechnology | Series A | $49.5M | 81% |
See where Locus Solutions, LLC/OH sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Locus Solutions, LLC/OH, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.